Abstract 2885
Background
Cancer-associated thrombosis (CAT) is a well–known complication of cancer, especially pancreatic cancer. One possible cause of CAT is secretion of tissue factor (TF)-positive extracellular vesicles from cancer cells. The previous cohort of Western countries showed that patients (pts) with a high level of TF tended to develop CAT with 20–40% incidence in pancreatic cancer. This prospective cohort study aimed to assess the efficacy of TF level for predicting the incidence of CAT in Japanese pts with pancreatic cancer.
Methods
We registered consented 197 pts from June 2013 to November 2016, who had pathologically confirmed pancreatic cancer and no history of treatment for the current disease. Plasma samples were collected from pts at the time of registration, 3, 6, and 12 months after. The TF level was evaluated using the Quantikine® ELISA kit (R&D systems) as we found that TF levels in multiple cancer cell lines evaluated using this kit correlated well with those analyzed by western blotting experiments. We estimated the positive (PPV) and negative predictive values (NPV) for the incidence of CAT by using obtained plasma TF levels (cutoff value: 100 pg/ml) and D-dimer levels (cutoff value: 1.2 μg/ml).
Results
Of all the patients, 189 patients were with unresectable disease. The median of the initial level of TF for these pts was 47.8 pg/ml (range: 0.0—318.7). The incidence of CAT was observed in 13 pts (6.6%) at the median follow-up time of 325 days. The median TF level at the time of registration was 148.5 pg/ml in CAT+ group and 53.5 pg/ml in CAT- group with a p–value of < 0.0001. PPV and NPV estimated by TF levels at the time of registration were 23.1% and 94.6%, and by the D-dimer levels were 7.2% and 92.4%, respectively. In pts with a D-dimer level >1.2 µg/ml, NPV by TF < 100 pg/ml was 95%. Similar results were obtained when TF levels of 3 months before the onset of CAT were used.
Conclusions
Present study revealed that the incidence of CAT in Japanese pts was lower than that of Western countries. It was also found that TF levels alone could not predict CAT observed in Japanese pts with pancreatic cancer: however, TF levels were found to contribute to high NPV even in pts with a high level of D–dimer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract